Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration, PMID: 23084240
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial, PMID: 26935357
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T, PMID: 28837425
Intravitreal Ziv-Aflibercept: A Comprehensive Review, PMID: 31314638
Aflibercept for neovascular age-related macular degeneration, PMID: 26857947
SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB, PMID: 28106709
Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial, PMID: 28551167
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial, PMID: 29392288
Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations, PMID: 32664269
Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry, PMID: 31932092
Aflibercept, PMID: 23444216
The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective, PMID: 29772018
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen, PMID: 22949147
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration, PMID: 30986442
Aflibercept, PMID: 22460118
Aflibercept: A review of its effect on the treatment of exudative age-related macular degeneration, PMID: 30813810
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy, PMID: 30765771
Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab, PMID: 28448655
Aflibercept: A Review in Metastatic Colorectal Cancer, PMID: 26220913
Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies, PMID: 31728825
A Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Patients with Visual Impairment due to Diabetic Macular Edema (KITE), PMID: 32131127
Intravitreal Ziv-Aflibercept: Clinical Effects and Economic Impact, PMID: 28971631
Aflibercept: A Review of Its Use in the Management of Diabetic Eye Complications, PMID: 27166390
Potential of subconjunctival aflibercept in treating choroidal neovascularization, PMID: 32795527
Aflibercept (VEGF-TRAP): the next anti-VEGF drug, PMID: 21999177
Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD, PMID: 25001321
Aflibercept: A Review in Macular Oedema Secondary to Branch Retinal Vein Occlusion, PMID: 28365905
Ziv-aflibercept (Zaltrap) for the treatment of metastatic colorectal cancer, PMID: 24259608
Aflibercept: A Review of Its Use in Diabetic Macular Oedema, PMID: 26056030
Intravitreal Aflibercept in Diabetic Macular Edema: Long-Term Outcomes, PMID: 28427067
Aflibercept in the Treatment of Diabetic Macular Edema: A Review and Consensus Paper, PMID: 29077188
Transport and fate of aflibercept in VEGF-A 165-challenged retinal endothelial cells, PMID: 32712182
Aflibercept in age-related macular degeneration: evaluating its role as a primary therapeutic option, PMID: 28548650
Aflibercept for the treatment of diabetic macular edema, PMID: 26907516
Influence of aflibercept on platelet activation profile, PMID: 29908884
A preclinical and clinical review of aflibercept for the management of cancer, PMID: 22264850
Aflibercept for age-related macular degeneration: a game-changer or quiet addition?, PMID: 22813448
Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration, PMID: 29476754
Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity, PMID: 31124509
Aflibercept for intravitreal injection: in neovascular age-related macular degeneration, PMID: 23038609
Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer, PMID: 24128964
Aflibercept a new target therapy in cancer treatment: a review, PMID: 26224565
Evaluation of aflibercept in the treatment of metastatic colorectal cancer, PMID: 25152076
INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB INJECTIONS FOR TYPE 3 NEOVASCULARIZATION, PMID: 28984737
HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration, PMID: 32574761
Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration, PMID: 26076760
Aflibercept regulates retinal inflammation elicited by high glucose via the PlGF/ERK pathway, PMID: 31351870
PHARMACOKINETIC STUDY OF INTRAVITREAL AFLIBERCEPT IN HUMANS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION, PMID: 31145389
Aflibercept (eylea) for age-related macular degeneration, PMID: 22354219
Aflibercept: an update on recent milestones achieved, PMID: 25588083
For research use only. Not for human or drug use.
